Galectin Therapeutics GALT Stock
Galectin Therapeutics Price Chart
Galectin Therapeutics GALT Financial and Trading Overview
| Galectin Therapeutics stock price | 1.28 USD |
| Previous Close | 1.45 USD |
| Open | 1.46 USD |
| Bid | 0 USD x 1400 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.44 - 1.48 USD |
| 52 Week Range | 1.02 - 2.57 USD |
| Volume | 42.51K USD |
| Avg. Volume | 48.12K USD |
| Market Cap | 86.99M USD |
| Beta (5Y Monthly) | 1.399647 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.76 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GALT Valuation Measures
| Enterprise Value | 122.21M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.4313726 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Galectin Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.399647 |
| 52-Week Change | 21.66% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.57 USD |
| 52 Week Low | 1.02 USD |
| 50-Day Moving Average | 1.74 USD |
| 200-Day Moving Average | 1.58 USD |
GALT Share Statistics
| Avg. Volume (3 month) | 48.12K USD |
| Avg. Daily Volume (10-Days) | 43.6K USD |
| Shares Outstanding | 59.58M |
| Float | 42.29M |
| Short Ratio | 43.86 |
| % Held by Insiders | 29.03% |
| % Held by Institutions | 12.07% |
| Shares Short | 2.09M |
| Short % of Float | 38.65% |
| Short % of Shares Outstanding | 3.50% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -89.98% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -40484000 USD |
| Diluted EPS (ttm) | -0.67 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 17.8M USD |
| Total Cash Per Share (mrq) | 0.3 USD |
| Total Debt (mrq) | 51.38M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.695 |
| Book Value Per Share (mrq) | -0.753 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33807000 USD |
| Levered Free Cash Flow (ttm) | -20172624 USD |
Profile of Galectin Therapeutics
| Country | United States |
| State | GA |
| City | Norcross |
| Address | 4960 Peachtree Industrial Boulevard |
| ZIP | 30071 |
| Phone | 678 620 3186 |
| Website | https://galectintherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 12 |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Q&A For Galectin Therapeutics Stock
What is a current GALT stock price?
Galectin Therapeutics GALT stock price today per share is 1.28 USD.
How to purchase Galectin Therapeutics stock?
You can buy GALT shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Galectin Therapeutics?
The stock symbol or ticker of Galectin Therapeutics is GALT.
Which industry does the Galectin Therapeutics company belong to?
The Galectin Therapeutics industry is Biotechnology.
How many shares does Galectin Therapeutics have in circulation?
The max supply of Galectin Therapeutics shares is 67.97M.
What is Galectin Therapeutics Price to Earnings Ratio (PE Ratio)?
Galectin Therapeutics PE Ratio is now.
What was Galectin Therapeutics earnings per share over the trailing 12 months (TTM)?
Galectin Therapeutics EPS is -0.76 USD over the trailing 12 months.
Which sector does the Galectin Therapeutics company belong to?
The Galectin Therapeutics sector is Healthcare.
Galectin Therapeutics GALT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17146.39 USD — |
-1.36
|
6.49B USD — | 17133.29 USD — | 17467.35 USD — | — - | 6.49B USD — |
| NASDAQ Capital Market Composite RCMP | 100.87 USD — |
-1.25
|
— — | 100.83 USD — | 103.65 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 924.57 USD — |
+0.11
|
— — | 923.44 USD — | 934.48 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21024.86 USD — |
-1.19
|
— — | 20973.2 USD — | 21382.13 USD — | — - | — — |
- {{ link.label }} {{link}}